Contineum Therapeutics (CTNM)

• Market cap: $371M
• 1 day: 1.91%
• 5 days: 2.56%
• 1 month: -6.18%
• 3 months: -23.39%
• 6 months: -24.91%
• Year to date: -6.43%
• 1 year: -6.43%
• 5 years: -6.43%
• 10 years: -6.43%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

29% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 7

12% more capital invested

Capital invested by funds: $229M [Q2] → $256M (+$26.7M) [Q3]

4% more funds holding

Funds holding: 49 [Q2] → 51 (+2) [Q3]

3.0% more ownership

Funds ownership: 68.61% [Q2] → 71.6% (+3.0%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]

13% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 16

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $31 115% upside
• Avg. target: $32 119% upside
• High target: $32 122% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

RBC Capital Brian Abrahams 14% 1-year accuracy 11 / 79 met price target	115% upside $31	Outperform Maintained	7 Nov 2024
Baird Joel Beatty 48% 1-year accuracy 21 / 44 met price target	122% upside $32	Outperform Initiated	22 Oct 2024